​​

Leiam is led by a senior regulatory and development professional with over a decade of experience across global pharma and biotech environments.

​

Experience includes program-level regulatory strategy ownership for biologics and vaccines, direct engagement with Singapore’s Health Sciences Authority (HSA), and FDA interaction as a scientific and regulatory subject-matter expert.

​

Unlike large consultancies, Leiam offers direct access to senior-level judgment, grounded in hands-on development experience and an understanding of how regulatory strategy, clinical planning, and scientific positioning intersect in practice.

​

• Former regulatory and development leadership roles in global pharma and biotech

• Primary regulatory interface with HSA; successful CTA experience

• FDA engagement through briefing documents, protocols, and regulatory meetings

• RAC (Drugs) certified